ZyVersa Therapeutics Inc.

0.73
0.02 (3.11%)
At close: Apr 24, 2025, 12:21 PM

Company Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.

It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.

ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc. logo
Country United States
IPO Date Feb 11, 2022
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Stephen C. Glover

Contact Details

Address:
2200 N. Commerce Parkway
Weston, Florida
United States
Website https://www.zyversa.com

Stock Details

Ticker Symbol ZVSA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001859007
CUSIP Number 98987D201
ISIN Number US98987D2018
Employer ID 86-2685744
SIC Code 2834

Key Executives

Name Position
Stephen C. Glover Co-Founder, Chairman, Chief Executive Officer & President
Peter Wolfe Chief Financial Officer & Secretary
Dr. Pablo A. Guzman FACC, M.D. Chief Medical Officer, Senior Vice President of Medical Affairs & Chairman of Renal Scientific Advisory Board

Latest SEC Filings

Date Type Title
Apr 17, 2025 ARS Filing
Apr 17, 2025 DEFA14A Filing
Apr 17, 2025 DEF 14A Filing
Apr 07, 2025 PRE 14A Filing
Apr 07, 2025 8-K Current Report
Apr 04, 2025 S-3 Filing
Mar 27, 2025 10-K Annual Report
Mar 07, 2025 8-K Current Report
Jan 24, 2025 S-8 Filing
Jan 17, 2025 DEF 14A Filing